Public consultation – FDA Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry (Cell and Gene Therapy Catapult – Regulatory Round-up – January 2023)
End date :14 March 2023
Category: Draft guidance
See all of Catapult’s Regulatory Round-up for January 2023 here. Published on the 1st of February 2023.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (17 mai 2023). Public consultation – FDA Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry (Cell and Gene Therapy Catapult – Regulatory Round-up – January 2023). ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/o6b0





